Home » Blog » 21st Century Cures Act, Scalp Cooling Technology, and Looking Forward to 2017

21st Century Cures Act, Scalp Cooling Technology, and Looking Forward to 2017


IP Blog | Dave Melin | December 18, 2016

BioBlog Weekly

This week’s BioBlog contains articles about the 21st Century Cures Act that was signed this past week,  scalp cooling technology seeks FDA clearance, 2017 industry projections, and more.

The 21st Century Cures Act — A View from the NIH

This article from the New England Journal of Medicine focuses on aspects of the Cures Act that are directly relevant to the NIH’s mission.

ASCO CEO Dr. Clifford Hudis Commends President Obama, Vice President Biden, and Congress During 21st Century Cures Act Signing Ceremony at the White House

“This historic legislation brings new hope to millions of Americans facing life-threatening diseases and to their families,” states Dr. Hudis.

Obama Signs Bill Boosting Spending on Cancer Research

ABC News reports: On a “bittersweet day” that brought back memories of loved ones lost, President Barack Obama signed into law legislation that makes new investments in cancer research and battling drug abuse.

UK-based Paxman Seeks FDA Clearance For Advanced Scalp Cooling Technology

The pioneering Paxman Scalp Cooling System device, developed in the UK, has been shown in clinical trials to preserve hair in more than 50% of the women who used it.

2017: A Year of Emerging Technologies, Partnerships and Value-Based Care

Fierce Healthcare reports that PwC Health Research Institute foresees that healthcare executives will continue their work on value-based care, prepare for emerging technologies and collaborate with former competitors through joint ventures, partnerships, strategic alliances and clinical affiliations.

Express Scripts Sees No Let-Up in Drug Pricing Chatter

This piece from Reuters notes that although President-elect Donald Trump pledged last week to “bring down drug prices,” prescription benefit managers (PBMs) have in recent years taken an increasingly aggressive stance in price negotiations with drugmakers.

 


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *